| Title |
TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer
|
|---|---|
| Published in |
Annals of Surgical Oncology, May 2016
|
| DOI | 10.1245/s10434-016-5240-1 |
| Pubmed ID | |
| Authors |
Stephanie A. Valente, Rahul D. Tendulkar, Sheen Cherian, Colin O’Rourke, Jon M. Greif, Lisa Bailey, Valery Uhl, Kevin P. Bethke, Eric D. Donnelly, Ray Rudolph, Aaron Pederson, Thomas Summer, S. Chace Lottich, Darrel L. Ross, Christine Laronga, Loretta Loftus, Andrea M. Abbott, Pond Kelemen, Ulrich Hermanto, Neil B. Friedman, Gauri C. Bedi, Jennifer E. Joh, William A. Thompson, Richard A. Hoefer, Jason P. Wilson, Song K. Kang, Barry Rosen, James Ruffer, Luis Bravo, Alice Police, Jamie M. Escallon, Anthony W. Fyles, David R. McCready, Gregory M. Graves, Nitin Rohatgi, Joyce A. Eaker, Jannine Graves, Shawna C. Willey, Eleni A. Tousimis, Brian T. Collins, Christina M. Shaw, Lee Riley, Nimisha Deb, Tricia Kelly, David L. Andolino, Marc E. Boisvert, Joanne Lyons, William Small, Stephen R. Grobmyer |
| Abstract |
Single-dose intraoperative radiotherapy (IORT) is an emerging treatment for women with early stage breast cancer. The objective of this study was to define the frequency of IORT use, patient selection, and outcomes of patients treated in North America. A multi-institutional retrospective registry was created, and 19 institutions using low-kilovoltage IORT for the treatment of breast cancer entered data on patients treated at their institution before July 31, 2013. Patient selection, IORT treatment details, complications, and recurrences were analyzed. From 2007 to July 31, 2013, a total of 935 women were identified and treated with lumpectomy and IORT. A total of 822 patients had at least 6 months' follow-up documented and were included in the analysis. The number of IORT cases performed increased significantly over time (p < 0.001). The median patient age was 66.8 years. Most patients had disease that was <2 cm in size (90 %) and was estrogen positive (91 %); most patients had invasive ductal cancer (68 %). Of those who had a sentinel lymph node procedure performed, 89 % had negative sentinel lymph nodes. The types of IORT performed were primary IORT in 79 %, secondary IORT in 7 %, or planned boost in 14 %. Complications were low. At a median follow-up of 23.3 months, crude in-breast recurrence was 2.3 % for all patients treated. IORT use for the treatment of breast cancer is significantly increasing in North America, and physicians are selecting low-risk patients for this treatment option. Low complication and local recurrence rates support IORT as a treatment option for selected women with early stage breast cancer. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| Spain | 1 | 11% |
| United Arab Emirates | 1 | 11% |
| Philippines | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 15% |
| Student > Bachelor | 5 | 13% |
| Student > Ph. D. Student | 5 | 13% |
| Researcher | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 16 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 43% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Computer Science | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 16 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2022.
All research outputs
#3,772,322
of 23,853,707 outputs
Outputs from Annals of Surgical Oncology
#1,066
of 6,758 outputs
Outputs of similar age
#57,973
of 304,979 outputs
Outputs of similar age from Annals of Surgical Oncology
#22
of 111 outputs
Altmetric has tracked 23,853,707 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,758 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,979 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 111 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.